ICER president Steven Pearson at JPM23 (Adrien Villez for Endpoints News)
January 17, 2023 03:19 PM EST
Pharma

ICER: Ma­jor­i­ty of pay­er cov­er­age poli­cies sup­port 'key el­e­ments of fair ac­cess' in for­mu­la­ries

Paul Schloesser

Associate Editor

The cost-ef­fec­tive­ness watch­dog ICER took a look at 19 drugs and com­pared them to pay­er cov­er­age poli­cies — find­ing in its newest re­port that pay­ers, more …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times